{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,31]],"date-time":"2025-08-31T10:16:50Z","timestamp":1756635410518,"version":"3.41.0"},"reference-count":20,"publisher":"Medical Association of Nippon Medical School","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Nippon Med Sch"],"published-print":{"date-parts":[[2025,4,20]]},"DOI":"10.1272\/jnms.jnms.2025_92-212","type":"journal-article","created":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T22:10:54Z","timestamp":1747779054000},"page":"204-215","source":"Crossref","is-referenced-by-count":1,"title":["Real-World Experience with Triplet Therapy for High-Volume Metastatic Castration-Sensitive Prostate Cancer: A Retrospective Cohort Study from a Japanese Academic Hospital"],"prefix":"10.1272","volume":"92","author":[{"given":"Jun","family":"Akatsuka","sequence":"first","affiliation":[{"name":"Department of Urology, Nippon Medical School"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Go","family":"Kimura","sequence":"additional","affiliation":[{"name":"Department of Urology, Nippon Medical School"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mami","family":"Takadate","sequence":"additional","affiliation":[{"name":"Department of Urology, Nippon Medical School"},{"name":"Pathology Informatics Team, RIKEN Center for Advanced Intelligence Project"},{"name":"Mathematical Intelligence for Medicine, Graduate School of Medicine, Tohoku University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroya","family":"Hasegawa","sequence":"additional","affiliation":[{"name":"Department of Urology, Nippon Medical School"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hikaru","family":"Mikami","sequence":"additional","affiliation":[{"name":"Department of Urology, Nippon Medical School"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kotaro","family":"Obayashi","sequence":"additional","affiliation":[{"name":"Department of Urology, Nippon Medical School"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hayato","family":"Takeda","sequence":"additional","affiliation":[{"name":"Department of Urology, Nippon Medical School"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuki","family":"Endo","sequence":"additional","affiliation":[{"name":"Department of Urology, Nippon Medical School"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shogo","family":"Imai","sequence":"additional","affiliation":[{"name":"Department of Radiology, Nippon Medical School"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuka","family":"Toyama","sequence":"additional","affiliation":[{"name":"Department of Urology, Nippon Medical School"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoichiro","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"Pathology Informatics Team, RIKEN Center for Advanced Intelligence Project"},{"name":"Mathematical Intelligence for Medicine, Graduate School of Medicine, Tohoku University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yukihiro","family":"Kondo","sequence":"additional","affiliation":[{"name":"Department of Urology, Nippon Medical School"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"21","reference":[{"key":"1","unstructured":"1. National Cancer Center (JP), Institute for Cancer Control. [Cancer Information Service] [Internet]. Tokyo: National Cancer Center (JP), Institute for Cancer Control; 2024 Jun 21. Available from: https:\/\/ganjoho.jp. Japanese."},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Schroder FH, Hugosson J, Roobol MJ, et al. Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up. Lancet. 2014 Dec 6;384 (9959):2027-35.","DOI":"10.1016\/S0140-6736(14)60525-0"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Siegel DA, O&apos;Neil ME, Richards TB, Dowling NF, Weir HK. Prostate cancer incidence and survival, by stage and race\/ethnicity - United States, 2001-2017. MMWR Morb Mortal Wkly Rep. 2020 Oct 16;69 (41):1473-80.","DOI":"10.15585\/mmwr.mm6941a1"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Fizazi K, Tran N, Fein L, et al. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N Engl J Med. 2017 Jul 27;377 (4):352-60.","DOI":"10.1056\/NEJMoa1704174"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Chi KN, Agarwal N, Bjartell A, et al. Apalutamide for metastatic, castration-sensitive prostate cancer. N Engl J Med. 2019 Jul 4;381 (1):13-24.","DOI":"10.1056\/NEJMoa1903307"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Armstrong AJ, Szmulewitz RZ, Petrylak DP, et al. ARCHES: a randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer. J Clin Oncol. 2019 Nov 10;37 (32):2974-86.","DOI":"10.1200\/JCO.19.00799"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Sweeney CJ, Chen YH, Carducci M, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med. 2015 Aug 20;373 (8):737-46.","DOI":"10.1056\/NEJMoa1503747"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Fizazi K, Foulon S, Carles J, et al. Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 x 2 factorial design. Lancet. 2022 Apr 30;399 (10336):1695-707.","DOI":"10.1016\/S0140-6736(22)00367-1"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Smith MR, Hussain M, Saad F, et al. Darolutamide and survival in metastatic, hormone-sensitive prostate cancer. N Engl J Med. 2022 Mar 24;386 (12):1132-42.","DOI":"10.1056\/NEJMoa2119115"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Hussain M, Tombal B, Saad F, et al. Darolutamide plus androgen-deprivation therapy and docetaxel in metastatic hormone-sensitive prostate cancer by disease volume and risk subgroups in the phase III ARASENS Trial. J Clin Oncol. 2023 Jul 10;41 (20):3595-607.","DOI":"10.1200\/JCO.23.00041"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Akatsuka J, Kimura G, Obayashi K, et al. Outcomes of starting low-dose pazopanib in patients with metastatic renal cell carcinoma who do not meet eligibility criteria for clinical trials. Urol Sci. 2021 Jul-Sep;32 (3):104-10.","DOI":"10.4103\/UROS.UROS_145_20"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Kafka M, Giannini G, Artamonova N, et al. Real-world evidence of triplet therapy in metastatic hormone-sensitive prostate cancer: an Austrian multicenter study. Clin Genitourin Cancer. 2024 Apr;22 (2):458-466.e1.","DOI":"10.1016\/j.clgc.2023.12.018"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Urabe F, Imai Y, Goto Y, et al. Real-world evidence of triplet therapy efficacy in patients with metastatic castration-sensitive prostate cancer: a Japanese multicenter study. Jpn J Clin Oncol. 2024 Nov 2;54 (11):1208-13.","DOI":"10.1093\/jjco\/hyae098"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009 Jan;45 (2):228-47.","DOI":"10.1016\/j.ejca.2008.10.026"},{"key":"15","unstructured":"15. National Cancer Institute (US), Division of Cancer Treatment and Diagnosis. Common Terminology Criteria for Adverse Events (CTCAE) v5.0. 2017 [Internet]. Bethesda (MD): National Cancer Institute (US), Division of Cancer Treatment and Diagnosis; 2025 Jan 2. Available from: https:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/ctc.htm#ctc_50"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Uemura M, Kikukawa H, Hashimoto Y, et al. Darolutamide in Japanese patients with metastatic hormone-sensitive prostate cancer: Phase 3 ARASENS subgroup analysis. Cancer Med. 2024 Nov;13 (21):e70029.","DOI":"10.1002\/cam4.70029"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Sutera PA, Shetty AC, Hakansson A, et al. Transcriptomic and clinical heterogeneity of metastatic disease timing within metastatic castration-sensitive prostate cancer. Ann Oncol. 2023 Jul;34 (7):605-14.","DOI":"10.1016\/j.annonc.2023.04.515"},{"key":"18","doi-asserted-by":"publisher","unstructured":"18. Urabe F, Kagawa H, Yanagisawa T, et al. Comparative adverse event profiles of triplet therapy versus docetaxel-based therapy in patients with metastatic prostate cancer: a multicenter retrospective study. Prostate International [Internet]. 2024 Nov. Available from: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S2287888224000850. doi: 10.1016\/j.prnil.2024.11.003.","DOI":"10.1016\/j.prnil.2024.11.003"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Akatsuka J, Kimura G, Takadate M, et al. The current status of comprehensive genomic profiling in the management of metastatic castration-resistant prostate cancer: a study from a cooperative hospital for cancer genomic medicine in Japan. J Nippon Med Sch. 2024 Oct 25;91 (5):472-9.","DOI":"10.1272\/jnms.JNMS.2024_91-512"},{"key":"20","unstructured":"20. Grimm MO, Smith MR, Hussain MHA, et al. Post-progression survival of patients with metastatic hormone-sensitive prostate cancer who received darolutamide or placebo: post hoc analysis of ARASENS. Poster session presented at: 2024 American Society of Clinical Oncology (ASCO) Annual Meeting; 2024 May 31-Jun 4; Chicago, IL."}],"container-title":["Journal of Nippon Medical School"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jnms\/92\/2\/92_JNMS.2025_92-212\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,24]],"date-time":"2025-05-24T04:40:55Z","timestamp":1748061655000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jnms\/92\/2\/92_JNMS.2025_92-212\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,20]]},"references-count":20,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1272\/jnms.jnms.2025_92-212","relation":{},"ISSN":["1345-4676","1347-3409"],"issn-type":[{"type":"print","value":"1345-4676"},{"type":"electronic","value":"1347-3409"}],"subject":[],"published":{"date-parts":[[2025,4,20]]},"article-number":"JNMS.2025_92-212"}}